Legal & General Group Plc - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 110 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.

Quarter-by-quarter ownership
Legal & General Group Plc ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$18,460
-16.3%
15,6440.0%0.00%
Q2 2023$22,058
+47.1%
15,644
+61.7%
0.00%
Q1 2022$15,000
-37.5%
9,6740.0%0.00%
Q4 2021$24,0000.0%9,6740.0%0.00%
Q3 2021$24,000
-14.3%
9,6740.0%0.00%
Q2 2021$28,000
+154.5%
9,674
-29.6%
0.00%
Q1 2020$11,000
-42.1%
13,751
-35.0%
0.00%
Q4 2019$19,000
-9.5%
21,1700.0%0.00%
Q3 2019$21,00021,1700.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$85,694,0004.37%
Defender Capital, LLC. 4,798,270$12,707,0004.13%
Raffles Associates 93,590$236,0000.22%
Prescott General Partners LLC 1,851,851$4,667,0000.16%
DCF Advisers, LLC 87,000$219,0000.10%
Laidlaw Wealth Management LLC 104,841$264,0000.07%
Beirne Wealth Consulting Services, LLC 45,000$113,0000.06%
Strategic Wealth Investment Group, LLC 70,625$179,0000.05%
Fort Sheridan Advisors LLC 47,931$121,0000.04%
Sightline Wealth Advisors, LLC 14,958$38,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders